Take part in a paid clinical trial

This clinical trial is sponsored by a pharmaceutical company. It is investigating a potential drug (the study drug) for inflammatory and fibrotic conditions. These include long-term digestive diseases such as ulcerative colitis and Crohn’s disease, where ongoing inflammation and scarring can damage the intestines. Some current treatments may not work for everyone and can cause significant side effects. This trial is designed to assess the safety and potential benefits of an investigational study drug that may offer an additional option for people who do not respond well to existing therapies. This trial is being held in Brisbane.

We’re currently looking for adults aged 18 to 65 who are experiencing androgenetic alopecia (AGA), also known as pattern hair loss, to take part in The Headline Trial.

Hair loss is common and can affect both men and women. This clinical study is investigating new approaches that may help shape future treatment options.

You don’t need a formal diagnosis to get started. If you think you may have AGA, you can begin with a quick pre-screen. This helps us assess whether you may meet the initial study requirements. Completing the pre-screen doesn’t guarantee enrolment, but it’s an important first step in seeing whether the study may be suitable for you.

By getting involved, you’ll be contributing to research that aims to improve future options for people affected by hair loss.

This study is testing an investigational vaccine aimed at protecting against norovirus, a common cause of stomach bugs that can lead to symptoms like nausea, vomiting, and diarrhoea.

The research is looking at how safe the investigational vaccine is, how people’s bodies respond to it, and how it may help the immune system build protection. The study involves healthy adults aged 18 to 80.

Norovirus is one of the most common causes of gastro illness worldwide, and there is currently no approved vaccine available. This research aims to help change that by supporting the evaluation of an investigational vaccine that may potentially be a future prevention option.

Epstein–Barr virus (EBV) is a very common virus that most people catch at some point in their life, often without realising it. It spreads mainly through saliva, such as kissing or sharing drinks, and is best known for causing glandular fever. When symptoms do occur, they can include a sore throat, swollen glands, fever, and extreme tiredness that may last for several weeks.

Once someone is infected, EBV stays quietly in the body for life, usually without causing any problems. The immune system keeps the virus under control, and most people never notice it again. In some cases, people may feel lingering fatigue after the initial illness, or the virus may reactivate later without symptoms, but for the vast majority of people, EBV is mild and recovery is complete. This study is evaluating the safety and tolerability of a potential vaccine that aims to provide immunization against EBV and EBV related conditions.